SPON1 is an independent prognostic biomarker for ovarian cancer.

ABSTRACT:

Background

Ovarian cancer has the worst outcome among gynecological malignancies; therefore, biomarkers that could contribute to the early diagnosis and/or prognosis prediction are urgently required. In the present study, we focused on the secreted protein spondin-1 (SPON1) and clarified the prognostic relevance in ovarian cancer.

Methods

We developed a monoclonal antibody (mAb) that selectively recognizes SPON1. Using this specific mAb, we determined the expression of SPON1 protein in the normal ovary, serous tubal intraepithelial carcinoma (STIC), and ovarian cancer tissues, as well as in various normal adult tissues by immunohistochemistry, and verified its clinicopathological significance in ovarian cancer.

Results

The normal ovarian tissue was barely positive for

SUBMITTER: Miyakawa R 

PROVIDER: S-EPMC10182672 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature